# Nocturnal Glucose Profile According to Timing of Dinner Rapid Insulin and Basal and Rapid Insulin Type: An Insulclock® Connected Insulin Cap-Based Real-World Study

**Authors:** Fernando Gómez-Peralta, Xoan Valledor, Cristina Abreu, Elsa Fernández-Rubio, Laura Cotovad, Pedro Pujante, Sharona Azriel, Jesús Pérez-González, Alba Vallejo, Luis Ruiz-Valdepeñas, Rosa Corcoy

PMC · DOI: 10.3390/biomedicines12071600 · Biomedicines · 2024-07-18

## TL;DR

This study shows that when and what type of insulin is taken with dinner affects overnight blood sugar levels in people with type 1 diabetes.

## Contribution

The study provides real-world evidence on how insulin timing and type influence nocturnal glucose profiles in T1D patients.

## Key findings

- Delayed dinner insulin injections were linked to higher overnight glucose levels.
- Ultrarapid insulin reduced hypoglycemia and time below range compared to rapid insulin.
- Correction injections increased hypoglycemia and worsened glucose control overnight.

## Abstract

Background: A study to assess the glucose levels of people with type 1 diabetes (T1D) overnight, based on the insulin type and timing. Methods: A real-world, retrospective study of T1D, using multiple daily insulin injections. Continuous glucose monitoring and insulin injection data were collected for ten hours after dinner using the Insulclock® connected cap. Meal events were identified using the ROC detection methodology. The timing of the rapid insulin, second injections, and the type of insulin analogs used, were evaluated. Results: The nocturnal profiles (n = 775, 49 subjects) were analyzed. A higher glucose AUC of over 180 mg/dL was observed in subjects with delayed injections (number; %; mg/dL × h): −45–15 min (n = 136; 17.5%, 175.9 ± 271.0); −15–0 min (n = 231; 29.8%, 164.0 ± 2 37.1); 0 + 45 min (n = 408; 52.6%, 203.6 ± 260.9), (p = 0.049). The use of ultrarapid insulin (FiAsp®) (URI) vs. rapid insulin (RI) analogs was associated with less hypoglycemia events (7.1 vs. 13.6%; p = 0.005) and TBR70 (1.7 ± 6.9 vs. 4.6 ± 13.9%; p = 0.003). Users of glargine U300 vs. degludec had a higher TIR (70.7 vs. 58.5%) (adjusted R-squared: 0.22, p < 0.001). The use of a correction injection (n = 144, 18.6%) was associated with a higher number of hypoglycemia events (18.1 vs. 9.5%; p = 0.003), TBR70 (5.5 ± 14.2 vs. 3.0 ± 11.1%; p = 0.003), a glucose AUC of over 180 mg/dL (226.1 ± 257.8 vs. 178.0 ± 255.3 mg/dL × h; p = 0.001), and a lower TIR (56.0 ± 27.4 vs. 62.7 ± 29.6 mg/dL × h; p = 0.004). Conclusion: The dinner rapid insulin timing, insulin type, and the use of correction injections affect the nocturnal glucose profile in T1D.

## Linked entities

- **Chemicals:** FiAsp® (PubChem CID 16132418), degludec (PubChem CID 118984462)
- **Diseases:** type 1 diabetes (MONDO:0005147)

## Full-text entities

- **Genes:** INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}
- **Diseases:** T1D (MESH:D003922), hypoglycemia (MESH:D007003)
- **Chemicals:** glargine U300 (-), Glucose (MESH:D005947), degludec (MESH:C571886)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11274448/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11274448/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC11274448/full.md

---
Source: https://tomesphere.com/paper/PMC11274448